These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26094124)

  • 1. Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion protein.
    McCue J; Kshirsagar R; Selvitelli K; Lu Q; Zhang M; Mei B; Peters R; Pierce GF; Dumont J; Raso S; Reichert H
    Biologicals; 2015 Jul; 43(4):213-9. PubMed ID: 26094124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion protein.
    McCue J; Osborne D; Dumont J; Peters R; Mei B; Pierce GF; Kobayashi K; Euwart D
    Haemophilia; 2014 Jul; 20(4):e327-35. PubMed ID: 24811361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the toxicology and pharmacokinetics of recombinant factor VIII Fc fusion protein in animals.
    Dumont JA; Loveday KS; Light DR; Pierce GF; Jiang H
    Thromb Res; 2015 Dec; 136(6):1266-72. PubMed ID: 26514955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of recombinant factor VIII Fc fusion protein.
    Nestorov I; Neelakantan S; Ludden TM; Li S; Jiang H; Rogge M
    Clin Pharmacol Drug Dev; 2015; 4(3):163-74. PubMed ID: 27140796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A.
    Nolan B; Mahlangu J; Perry D; Young G; Liesner R; Konkle B; Rangarajan S; Brown S; Hanabusa H; Pasi KJ; Pabinger I; Jackson S; Cristiano LM; Li X; Pierce GF; Allen G
    Haemophilia; 2016 Jan; 22(1):72-80. PubMed ID: 26218032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A.
    Mahlangu JN; Ragni M; Gupta N; Rangarajan S; Klamroth R; Oldenburg J; Nogami K; Young G; Cristiano LM; Dong Y; Allen G; Pierce GF; Robinson B
    Thromb Haemost; 2016 Jul; 116(1):1-8. PubMed ID: 26962852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics.
    Casademunt E; Martinelle K; Jernberg M; Winge S; Tiemeyer M; Biesert L; Knaub S; Walter O; Schröder C
    Eur J Haematol; 2012 Aug; 89(2):165-76. PubMed ID: 22690791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budget Impact Analysis of Prolonged Half-Life Recombinant FVIII Therapy for Hemophilia in the United States.
    McMullen S; Buckley B; Hall E; Kendter J; Johnston K
    Value Health; 2017 Jan; 20(1):93-99. PubMed ID: 28212975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development, upscaling and validation of the purification process for human-cl rhFVIII (Nuwiq®), a new generation recombinant factor VIII produced in a human cell-line.
    Winge S; Yderland L; Kannicht C; Hermans P; Adema S; Schmidt T; Gilljam G; Linhult M; Tiemeyer M; Belyanskaya L; Walter O
    Protein Expr Purif; 2015 Nov; 115():165-75. PubMed ID: 26318235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the virus clearance capacity and robustness of the manufacturing process for the recombinant factor VIII protein, turoctocog alfa.
    Ellgaard TW; Bindslev L; Kamstrup S
    Protein Expr Purif; 2017 Jan; 129():94-100. PubMed ID: 27620499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia.
    Shapiro A
    Expert Opin Biol Ther; 2013 Sep; 13(9):1287-97. PubMed ID: 23930915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy.
    Meeks SL; Lacroix-Desmazes S
    Haemophilia; 2020 Nov; 26(6):958-965. PubMed ID: 32885562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant factor VIII Fc fusion protein drives regulatory macrophage polarization.
    Kis-Toth K; Rajani GM; Simpson A; Henry KL; Dumont J; Peters RT; Salas J; Loh C
    Blood Adv; 2018 Nov; 2(21):2904-2916. PubMed ID: 30396910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. rFVIIIFC for hemophilia A prophylaxis.
    Mahlangu J
    Expert Rev Hematol; 2018 Dec; 11(12):937-943. PubMed ID: 30449223
    [No Abstract]   [Full Text] [Related]  

  • 15. Demonstration of robust host cell protein clearance in biopharmaceutical downstream processes.
    Shukla AA; Jiang C; Ma J; Rubacha M; Flansburg L; Lee SS
    Biotechnol Prog; 2008; 24(3):615-22. PubMed ID: 18410156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process.
    Furuya K; Murai K; Yokoyama T; Maeno H; Takeda Y; Murozuka T; Wakisaka A; Tanifuji M; Tomono T
    Vox Sang; 2006 Aug; 91(2):119-25. PubMed ID: 16907872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective Evaluation of Cycled Resin in Viral Clearance Studies-A Multiple Company Collaboration.
    Mattila J; Curtis S; Webb-Vargas Y; Wilson E; Galperina O; Roush D; Tobler S; Stanley B; Clark M; Weaver J; Pike J; Yu D; Li X; Flicker A; Kindermann J; Schuelke N; Whitcombe R; Bennett L
    PDA J Pharm Sci Technol; 2019; 73(5):470-486. PubMed ID: 31101706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of a novel affinity adsorbent for the capture and purification of recombinant factor VIII compounds.
    McCue JT; Selvitelli K; Walker J
    J Chromatogr A; 2009 Nov; 1216(45):7824-30. PubMed ID: 19800068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Affinity chromatography to remove viruses during preparation of plasma derivatives.
    Lawrence JE
    Dev Biol Stand; 1993; 81():191-7. PubMed ID: 8174803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular design and downstream processing of turoctocog alfa (NovoEight), a B-domain truncated factor VIII molecule.
    Ahmadian H; Hansen EB; Faber JH; Sejergaard L; Karlsson J; Bolt G; Hansen JJ; Thim L
    Blood Coagul Fibrinolysis; 2016 Jul; 27(5):568-75. PubMed ID: 26761578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.